
REFERENCES

A

1. **Abess A, Keel DM and Graham BS (2003):** Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. *Arch Dermatol.*, 139: 337–339.
2. **Aggarwal H, Saxena A, Lubana PS et al. (2008):** Treatment of keloids and hypertrophic scars using bleomycin. *Cosm Dermatol.*, 7: 43-49.
3. **Al-Attar A, Mess S, Thomassen JM et al. (2006):** Keloid pathogenesis and treatment. *Plast Reconstr Surg.*, 117(1): 286-300.
4. **Alster T (2003):** Laser scar revision: comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. *Dermatol Surg.*, 29(1): 25-29.
5. **Alster TS and Tanzi EL (2003):** Hypertrophic scars and keloids: etiology and management. *Am J Clin Dermatol.*, 4(4): 235-243.
6. **Altaykan A, Boztepe G, Erkin G et al. (2004):** Acute generalized exanthematous pustulosis induced by bleomycin and confirmed by patch testing. *J Dermatol Treat.*, 15: 231–234.
7. **Anderson PJ (2005):** Apocrine hydrocysadenoma of the ear. *Otolaryngol Head Neck Surg.*, 133:981–982.
8. **Armour A, Scott PG and Tredget EE (2007):** Cellular and molecular pathology of HTS: basis for treatment. *Wound Repair Regen.*, 15 (1): 6–17.
9. **Asilian A, Darougheh A and Shariati F (2006):** New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. *Dermatol Surg.*, 32(7):907-915.
10. **Askew DA, Mickan SM, Soyer HP et al. (2009):** Effectiveness of 5-fluorouracil treatment for actinic keratosis-a systematic review of randomized controlled trials. *Int. J. Dermatol.*, 48: 453-463.

B

11. **Baryza MJ and Baryza GA (1995):** The Vancouver Scar Scale: An administration tool and its interrater reliability. *J Burn Care Rehabil.*, 16: 535-538.
12. **Berman B, Frankel S, Villa AM , et al. (2005):** Double-blind, randomized, placebo-controlled, prospective study evaluating the tolerability and effectiveness of imiquimod applied to postsurgical excisions on scar cosmesis. *Dermatol Surg.*, 31(11): 1399-1403.
13. **Berman B, Viera MH, Amini S, et al. (2008):** Prevention and management of hypertrophic scars and keloids after burns in children. *J Craniofac Surg.*,19(4): 989-1006.
14. **Bock O, Yu H, Zitron S, et al. (2005):** Studies of transforming growth factors beta 1–3 and their receptors I and II in fibroblast of keloids and hypertrophic scars. *Acta Derm Venereol.*, 85: 216–220.
15. **Bodokh I and Brun P (1996):** Treatment of keloids with intralesional bleomycin *Ann Dermatol Venereol.*, 123 (12): 791- 794.
16. **Brown JJ and Bayat A (2009):** Genetic susceptibility to raised dermal scarring. *Br J Dermatol.*, 161: 8–18.
17. **Bullard KM, Longaker MTand Lorenz HP (2003):** Fetal wound healing: current biology. *World J Surg.*, 27: 54–61.
18. **Burns RA, Roy JS, Woods C, et al. (2000):** Report of the first human case of lobomycosis in the United States. *J Clin Microbiol.*, 38: 1283–1285
19. **Butler PD, Longaker MT and Yang GP (2008):** Current Progress in Keloid: Research and Treatment. *J Amer College Surg.*, 206(4): 731-741

C

20. **Calabresi P and Chabner BA (2001):** Chemotherapy of neoplastic diseases. In: Goodman and Gillman. *The pharmacological basis of therapeutics*, 10th ed. By Hardman JE, Limbird LE and Gillman AG (eds), McGraw Hill, USA., pp. 1432-1434.

-
21. **Chabner BA and Longo DL (2001):** Cancer Chemotherapy & Biotherapy. Philadelphia: Lippincott Williams & Wilkins, pp. 466-481.
 22. **Chabner BA, Ryan DP and Pas-Ares L (2001):** Antineoplastic agents. In: Goodman & Gilman's: The pharmacological basis of therapeutics, 10th ed. McGraw Hill Medical Publish Division, New York, pp.1404
 23. **Chen J and Stubbe J (2005):** Bleomycins: towards better therapeutics. *Nature Reviews Cancer.*, 5: 102-112
 24. **Chiu LL, Sun CH, Yeh AT, et al. (2005):** Photodynamic therapy on keloid fibroblasts in tissue-engineered keratinocyte-fibroblast co-culture. *Lasers Surg Med.*, 37(3): 231-244.
 25. **Clark-Loeser LC, Washenik K and Shupack JL (2003):** Topical cytotoxic agents. In: Fitzpatrick's dermatology in general medicine. By Freedberg IM, Eisen AZ, Wolff K, Austen K, Goldsmith LA and Katz SI (eds), 6th ed, McGraw-Hill scientific publications, New York, pp. 2355-2356.
 26. **Copcu E, Aktas A, Sisman N, et al. (2003):** Thirty-one cases of Marjolin's ulcer. *Clin Exp Dermatol.*, 28: 138 –141.
 27. **Copcu E, Sivrioglu N and Oztan Y (2004):** Combination of surgery and intralesional verapamil injection in the treatment of the keloid. *J Burn Care Rehabil.*, 25(1): 1-7.
 28. **Cordeiro MF, Mead A, Ali RR, et al. (2003):** Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. *Gene Ther.*, 10: 59–71.
 29. **Correia O, Ribas F, Azevedo R et al. (2000):** Gangrene of the fingertips after bleomycin and methotrexate. *Cutis.*, 66:271–274.
 30. **Cutroneo KR (2007):** TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. *Wound Repair Regen.*, 15 (1): 554–560.

D

31. **Dammak A, Camus M, Anyfantakis V, et al. (2009):** Successful treatment of Hailey-Hailey disease with topical 5-fluorouracil. *Br J Dermatol.*, 161: 967-968.
 32. **D'Andrea F, Voza A, Brongo S, et al. (2001):** Dermatofibrosarcoma protuberans: experience with 14 cases. *J Eur Acad Dermatol Venereol.*, 15: 427– 429
-

33. **Darougheh A, Asilian A and Shariatic F (2007):** Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. *Clin Exper Dermatol.*, 34: 219-223.
34. **Davison SP, Mess S, Kauffman LC, et al. (2006):** Ineffective treatment of keloids with interferon alpha-2b. *Plast Reconstr Surg.*,117(1):247-252.
35. **Davison S, Dayan J, Clemens M, et al. (2009):** Efficacy of Intralesional 5-Fluorouracil and Triamcinolone in the Treatment of Keloids. *Aesth Surg J.*, 29(1):40-46.
36. **Dhar SB, Rashid MM, Islam AZ, et al. (2009):** Intralesional bleomycin in the treatment of cutaneous warts: A randomized clinical trial comparing it with cryotherapy. *Indian J Dermatol Venereol Leprol.*, 75: 262-266.
37. **Draelos ZD (2008):** The ability of onion extract gel to improve the cosmetic appearance of postsurgical scars. *J Cosmet Dermatol.*, 7(2):101-104.
38. **Draaijers LJ, Botman YA, Tempelman FR, et al. (2004):** Skin elasticity meter or subjective evaluation in scars: a reliability assessment. *Burns.*, 30(2):109-114.
39. **Duncan JAL, Bond JS, Mason T, et al. (2006):** Visual Analogue Scale scoring and ranking: a suitable and sensitive method for assessing scar quality. *PRS.*,118(4): 909-918.
40. **Durani P, McGrouther DA and Ferguson MWJ (2009):** Current scales for assessing human scarring: A review. *J Plastic Reconstr Aesth Surg.*, 62: 713-720.

E

41. **Eming SA, Krieg T and Davidson JM (2007):** Inflammation in wound repair: molecular and cellular mechanisms. *J Invest Dermatol.*, 127: 514–525.
42. **Erol OO, Gurlek A, Agaoglu G, et al. (2008):** Treatment of hypertrophic scars and keloids using intense pulsed light (IPL). *Aesthetic Plast Surg.*, 32(6): 902-909.
43. **España A, Solano T and Quintanilla E (2001):** Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. *Dermatol Surg.*, 27(1):23-27.
44. **Evan RF and Antoinette FH (2000):** Non-inflammatory disorders. In: *Pathology of the skin*, 2nd ed. McGraw Hill, New York, p. 670.

F

45. **Fearmonti R, Bond J, Erdmann D, et al. (2010):** A Review of Scar Scales and Scar Measuring Devices. *J Plast Surg.*, 10: 354-363.
46. **Figueroa S and Gennaro AR (1980):** Intralesional bleomycin injection in treatment of condyloma acuminatum. *Dis Colon Rect.*, 23: 550-551.
47. **Fitzpatrick RE (1999):** Treatment of inflamed hypertrophic scars using intralesional 5-FU. *Dermatol Surg.*, 25: 224–232.

G

48. **Garanziotis S, Steele MP and Schwartz DA (2004):** Pulmonary fibrosis: thinking outside of the lung. *J Clin Invest.*, 114:319-321.
49. **Garg MK, Weiss P, Sharma AK, et al. (2004):** Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external radiation. *Radiother Oncol.*, 73(2): 233-236.
50. **Gauglitz GG, Korting HC, Pavicic T, et al. (2011):** Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategies. *Mol Med.*, 17 (1): 113 – 125.
51. **Ghahary A and Ghaffari A (2007):** Role of keratinocytes fibroblast cross-talk in development of hypertrophic scar. *Wound Repair Regen.*, 15 (1): 546–553.
52. **Gonzalez-Vela MC, Val-Bernal JF, Gonzalez-Lopez MA, et al. (2006):** Sclerotic neurofibroma: a neurofibroma mimicking sclerotic fibroma. *J Cutan Pathol.*, 33: 47–50.
53. **Good L M, Miller MD and High WA (2010):** Intralesional agents have a role in the management of cutaneous malignancies: a review. *J Am Acad Dermatol.*, 11: 1-10.
54. **Gross K, Kircik L and Kricorian G (2007):** Five-fluorouracil 5% cream for treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. *Dermatol Surg.*, 33: 433-439.
55. **Gupta S and Kalra A (2002):** Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids. *Dermatol.*, 204: 130-2.

H

56. **Harunari N , Engrav LH , Armendariz RT , et al. (2008):** Comparison of Collagen Nodules and Mast Cells Between Human Hypertrophic Scar and Thick Scar of the Female Red Duroc Pig. *Int J Tissue Repair & Regeneration.*, 13 (2): A4 - A27
57. **Haudenschild DR, Nguyen B, Chen J, et al. (2008):** Rho kinase-dependent CCL20 induced by dynamic compression of human chondrocytes. *Arthritis Rheum.*, 58:2735-2742.
58. **Hayashi T, Nishihira J, Koyama Y, et al. (2006):** Decreased prostaglandin E2 production by inflammatory cytokine and lower expression of EP2 receptor result in increased collagen synthesis in keloid fibroblasts. *J Invest Dermatol.*, 126(5):990-997.
59. **Heller R, Jaroszeski MJ, Reintgen DS, et al. (1998):** Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. *Cancer.*, 83: 148-157.
60. **Hill BA (1971):** Principles of medical statistics. 9th ed. London. Lancet Limited Publications, 147: 383.
61. **Hosnuter M, Payasli C, Isikdemir A, et al. (2007):** The effects of onion extract on hypertrophic and keloid scars. *J Wound Care.*, 16(6): 251-254.

J

62. **Jiang D, Fu X, Chen W, et al. (2005):** Relationship between keloid proliferation and apoptosis of epithelial cell with destruction of structure and function of skin appendages. *J Clin Dermatol.*, 19(1): 15-19.

K

63. **Kakar AK, Shahzad M and Haroon TS (2006):** Keloids: clinical features and management. *J Pakis Assoc Dermatol.*, 16: 97-103.

64. **Kamp DW (2003):** Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited. *Chest*,124: 1187–1190.
65. **Kelly AP (2004):** Medical and surgical therapies for keloids. *Dermol Ther.*, 17:212.
66. **Kim A, DiCarlo J, Cohen C, et al. (2001):** Are keloids really "gli-oids"?: High-level expression of gli-1 oncogene in keloids. *J Am Acad Dermatol.*, 45(5):707-711.
67. **Klein MA and Burns LJ (2008):** Ocular side effects of chemotherapy. In: *Chemotherapy source book*, edited by Perry MC, 4th ed, Williams and Wilkins scientific publications, Lippincott, pp. 175.
68. **Koc E, Arca E, Surucu B, et al. (2008):** An open, randomized, controlled, comparative study of the combined effect of intralesional triamcinolone acetonide and onion extract gel and intralesional triamcinolone acetonide alone in the treatment of hypertrophic scars and keloids. *Dermatol Surg.*, 34(11): 1507-1514.
69. **Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, et al. (2005):** Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study. *J Am Acad Dermatol.*, 52(3): 474-479.
70. **Kopp J, Preis E, Said H, et al. (2005):** Abrogation of transforming growth factor-beta signaling by SMAD7 inhibits collagen gel contraction of human dermal fibroblasts. *J Biol Chem.*, 280: 1570–1576.
71. **Kose O and Waseem A (2008):** Keloids and hypertrophic scars: are they two different sides of the same coin?. *Dermatol Surg.*, 34: 336–346.
72. **Krebs HB (1991):** Treatment of genital condylomata with topical 5-fluorouracil. *Dermatol Clin.*, 9: 333-341.
73. **Kwan P, Hori K, Ding J, et al. (2009):** Scar and Contracture: Biological Principles. *Hand Clinics.*, 25 (4): 511-528.

L

74. **Ladak A and Tredget EE (2009):** Pathophysiology and management of the burn scar. *Clin Plast Surg.*, 36: 661–674.
75. **Lau JC, Li-Tsang CW and Zheng YP (2005):** Application of tissue ultrasound palpation system (TUPS) in objective scar evaluation. *Burns*,31:445-452.

-
76. **Lee JH, Kim SE and Lee AY (2008):** Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. *Int J Dermatol.*, 47(2):183-186.
 77. **Leventhal D, Furr M and Reiter D (2006):** Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. *Arch Facial Plast Surg.*, 8 : 362–368.
 78. **Lewis TG and Nydorf ED (2006):** Intralesional bleomycin for warts: a review. *J Drugs Dermatol .*, 5(6):499-504.
 79. **Lipke MM (2006):** An armamentarium of wart treatments. *Clin Med Res*, 4: 273-293.
 80. **Lobov IB, Brooks PC and Lang RA (2002):** Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. *Proc Natl Acad Sci USA.*, 99(17):11205-10.
 81. **Loven K, Stein L, Furst K et al. (2002):** Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. *Clin. Ther.*, 24: 990-1000.
 82. **Lye I, Edgar DW, Wood FM, et al. (2006):** Tissue tonometry is a simple, objective measure for pliability of burn scar: is it reliable? *J Burn Care Res.*, 27(1): 82-85.

M

83. **Magliaro A and Romanelli M (2003):** Skin hardness measurement in hypertrophic scars. *Wounds*,15: 66-70.
 84. **Manuskiatti W, Wanitphakdeedecha R and Fitzpatrick RE (2007):** Effect of pulse width of a 595-nm flashlamp-pumped pulsed dye laser on the treatment response of keloidal and hypertrophic sternotomy scars. *Dermatol Surg.*, 33(2):152-161.
 85. **Margaret Shanthi FX, Ernest K and Dhanraj P (2008):** Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. *Indian J Dermatol Venereol Leprol.*, 74(4): 343-348.
 86. **McEvoy GK (2004):** AHFS Drug Information, 46th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc., pp. 929-945.
-

-
87. **McEvoy GK (2006):** AHFS Drug Information, 48th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc., pp. 1661-1665.
 88. **McQuibban GA, Gong JH, Wong JP, et al. (2002):** Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. *Blood*, 100:1160–1167.
 89. **Meenakshi J, Jayaraman V, Ramakrishnan KM, et al. (2005):** Keloids and hypertrophic scars: a review. *Ind J Plast Surg.*, 28 (2): 175-179.
 90. **Meijer BU and de Waard-van der Spek FB (2007):** Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudix cream). *Contact Dermatitis*, 60: 57-58.
 91. **Micomonaco DC, Fung K, Mount G, et al. (2009):** Development of a new visual analogue scale for the assessment of area scars. *J Otolaryngol Head Neck Surg.*,38(1): 77-89.
 92. **Mikulec AA, Hanasono MM, Lum J, et al. (2001):** Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. *Arch Facial Plast Surg.*, 3(2):111-114.
 93. **Mofikoya BO, Adeyemo WL and Abdus-salam AA (2007):** Keloid and hypertrophic scars: a review of recent developments in pathogenesis and management. *Nig Q J Hosp Med .*,17(4):134-139.
 94. **Moore MM and Strober BE (2008):** Topical and intralesional cytotoxic agents. In: *Fitzpatrick's dermatology in general medicine*. By Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller A and Leffoll DJ (eds), 7th ed, McGraw-Hill scientific publications, New York, pp. 2122-2124.
 95. **Mrowietz U and Seifert O (2009):** Keloid Scarring: New Treatments Ahead. *Actas Dermo-Sifiliográficas.*, 100 (2): 75-83.
 96. **Muir T, Kirsten M, Fourie P et al. (2004):** Intralesional bleomycin injection for haemangiomas and congenital vascular malformations. *Pediatr Surg Int.*, 19: 766-773.
 97. **Mukhopadhyay A (2010):** Syndecan-2 and decorin: proteoglycans with a difference—implications in keloid pathogenesis. *J Trauma.*, 68:999–1008.
 98. **Muszynska A, Palka J and Gorodkiewicz E (2000):** The mechanism of daunorubicin-induced inhibition of prolidase activity in human skin fibroblasts and its implication to impaired collagen biosynthesis. *Exp Toxicol Pathol.*, 52(2): 149-155.
-

99. **Muszynska A, Wolczynski S and Palka J (2001):** The mechanism for anthracycline-induced inhibition of collagen biosynthesis. *Eur J Pharmacol.*, 411(1-2): 17-25.

N

100. **Naeini FF, Najafian J and Ahmadpour K (2006):** Bleomycin tattooing as a promising therapeutic modality in large keloids and hypertrophic scars. *Dermatol Surg.*, 32(8): 1023-1029.
101. **Nanda S and Reddy BS (2004):** Intralesional 5-fluorouracil as a treatment modality of keloids. *Dermatol Surg.*, 30(1):54-56.
102. **Niessen FB, Schalkwijk J, Vos H, et al. (2004):** Hypertrophic scar formation is associated with an increased number of epidermal Langerhans cells. *J Pathol.*, 202: 121–9.
103. **Noli C and Miolo A (2001):** The mast cell in wound healing. *Vet Dermatol.*, 12: 303–13.

O

104. **Occleston NL, O’Kane S, Goldspink N, et al. (2008):** New therapeutics for the prevention and reduction of scarring. *Drug Discovery Today*, 13(21): 973-981.
105. **Ogawa R, Mitsuhashi K, Oki K, et al. (2006):** A rare case of chondroid syringoma arising from the lower eyelid with ectropion. *Plast Reconstr Surg.*, 118: 137–140.
106. **Ogawa R, Akaishi S and Hyakusoku H (2009):** Differential and exclusive diagnosis of diseases that resemble keloids and hypertrophic scars. *Annals Plast Surg.*, 62 (6): 660–664.
107. **Oiso N, Kawara S and Kawada A (2008):** The effectiveness of narrowband ultraviolet B on hypertrophic scar in a patient having an isomorphic phenomenon and vitiligo. *J Eur Acad Dermatol Venereol.*, 22 (12): 1527 - 1535

P

108. **Paniz-Mondolfi AE, Reyes-Jaimes O, Davila-Jones L, et al. (2007):** Lobomycosis in Venezuela. *Int J Dermatol.*, 46:180 –185
109. **Pienaar C, Graham R, Geldenhuys S , et al. (2006):** Intralesional bleomycin for the treatment of hemangiomas. *Plast Reconstr Surg.*, 117: 221-226.
110. **Pizzo PA (2002):** Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, pp. 274-288.

R

111. **Rahban SR and Garner WL (2003):** Fibroproliferative scars. *Clinics Plast Surg.*, 30 (1): 77-89.
112. **Rivera A and Tyring SK (2004):** Therapy of cutaneous human Papillomavirus infections. *Dermatol Ther.*, 17: 441-448.
113. **Roques C, Téot L, Frasson N, et al. (2003):** PRIMOS: an optical system that produces three-dimensional measurements of skin surfaces. *J Wound Care.*,12(9): 362-364.
114. **Roques C and Teot L (2007):** A critical analysis of measurements used to assess and manage scars. *Int J Lower Extr Wounds*, 6(4): 249-253.
115. **Rothman RF, Liebmann JM and Ritch R (2000):** Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term follow up. *Ophthalmology*, 107 (6):1184-1190

S

116. **Sabater-Marco V, Perez-Valles A, Berzal-Cantalejo FF, et al. (2006):** Sclerosing dermatofibrosarcoma protuberans (DFSP): an unusual variant with focus on the histopathologic differential diagnosis. *Int J Dermatol.*, 45: 59–62

-
117. **Saitta P, Krishnamurthy K and Brown LH (2008):** Bleomycin in dermatology: a review of intralesional applications. *Dermatol Surg.*, 34: 1299-1313.
 118. **Salim A, Leman JA, McColl JH, et al. (2003):** Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. *Br J Dermatol.*, 148: 539-543.
 119. **Salk RS, Grogan KA and Chang TJ (2006):** Topical 5% 5-fluorouracil cream in the treatment of plantar warts: a prospective, randomized, and controlled clinical study. *J Drugs Dermatol.*, 5: 418-424.
 120. **Santiago M, de Castro DO Jr, Costa CA, et al. (2004):** Keloidal scleroderma. *Clin Rheumatol.*, 23: 50–51.
 121. **Saray Y and Güleç AT (2005):** Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: a preliminary study. *Int J Dermatol.*, 44(9): 777-784.
 122. **Sarov M and Stewart AF (2005):** The best control for the specificity of RNAi. *Trends Biotechnol.*, 23: 446-448.
 123. **Sartori S, Tassinari D, Ceccotti P, et al. (2004):** Prospective Randomized Trial of Intrapleural Bleomycin Versus Interferon Alfa-2b via Ultrasound-Guided Small-Bore Chest Tube in the Palliative Treatment of Malignant Pleural Effusions. *J Clin Oncol.*, 22(7): 1228-1233.
 124. **Saulis AS, Mogford JH, and Mustoe TA (2002):** Effect of Mederma on hypertrophic scarring in the rabbit ear model. *Plast Reconstr Surg.*, 110(1): 177-183.
 125. **Sayani K, Dodd CM, Nedelec B, et al. (2000):** Delayed appearance of decorin in healing burn scars. *Histopathology*, 36: 262–272.
 126. **Schlaak M and Simon JC (2010):** Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid- pilot study. *J Dtsch Dermatol Ges.*, 8: 174-178.
 127. **Sethi S, Mahajan BB, Gupta RR, et al. (2007):** Comparative evaluation of the therapeutic efficacy of dermabrasion, dermabrasion combined with topical 5% 5-fluorouracil cream, and dermabrasion combined with topical placentrex gel in localized stable vitiligo. *Int J Dermatol.*, 46: 875-879.
 128. **Shaffer JJ, Taylor SC, and Cook-Bolden F (2002):** Keloidal scars: a review with a critical look at therapeutic options. *J Am Acad Dermatol.*, 46: 63-97.
 129. **Sharquie KE and Al-Dhalimi MA (2003):** Keloid in Iraqi Patients: A clinicohistopathologic study. *Dermatol Surg.*, 29 (8): 847–851
-

130. **Shridharani SM, Magarakis M, Manson PN, et al. (2010):** The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars: A review. *Ann Plast Surg.*, 64 (3): 355-361.
131. **Slemp AE and Kirschner RE (2006):** Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. *Curr Opin Pediatr.*, 18 (4):396-402.
132. **Smith JC, Boone BE, Opalenik SR, et al. (2008):** Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. *J Invest Dermatol.*,128: 1298–1310.
133. **Sollitto RJ and Pizzano DM (1996):** Bleomycin sulfate in the treatment of mosaic plantar verrucae: A follow-up study. *J Foot Ankle Surg.*,35 (2): 169-172.
134. **Soyuer U and Aktaş E (1988):** Intralesional bleomycin therapy for leishmaniasis cutis. *Arch Dermatol.*, 124: 1571.
135. **Spann K, Mileski WJ, Atilas L, et al. (1996):** Use of a pneumatonometer in burn scar assessment. *J Burn Care Rehabil.*,17: 515-517.
136. **Steinkraus V and Boer A (2006):** Treatment of actinic keratoses: Why, when and how?. *Ind J Dermatol Venereol Leprol.*, 72 (5):331-333.
137. **Stulberg DL and Hutchinson AG (2003):** Molluscum contagiosum and warts. *Am Fam Physician.*, 67: 1233-1240.

T

138. **Taylor DK, Anstey AV, Coleman AJ, et al. (2002):** Guidelines for dosimetry and calibration in ultraviolet radiation therapy: a report of a British photodermatology group workshop. *BJD.*, 146 (5): 755-763.
139. **Truong PT, Lee JC, Soer B, et al. (2007):** Reliability and validity testing of the patient and observer scar assessment scale in evaluating linear scars after breast cancer surgery. *Plast Reconstr Surg.*,119(2):487-494.

U

- 140. Umebayashi Y, Enomoto H and Ogasawara M (2004):** Drug eruption due to bleomycin: an unusual form of Stevens–Johnson syndrome with pustules. *J Dermatol.*, 31: 802–5.

V

- 141. Vanhooteghem O, Richert B and de la Brassinne M (2001):** Raynaud phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin. *Pediatr Dermatol.*, 18: 249–251.
- 142. Van Triest B, Pinedo HM, Blaauwgeers JL, et al. (2000):** Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor and proliferation markers in colorectal cancer. *Clin Cancer Res.*, 6:1063-1072.
- 143. Vercelli S, Ferriero G, Santorio F, et al. (2009):** How to assess postsurgical scars: a review of outcome measures. *Disabil Rehabil.*, 31(25): 2055-2063.
- 144. Von Hilsheimer GE and Norton SA (2002):** Delayed bleomycin-induced hyperpigmentation and pressure on the skin. *J Am Acad Dermatol.*, 46: 642–643.

W

- 145. Wang Z, Lim IJ, Garron TM, et al. (2007):** Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. *J Plast Reconstr Aesthet Surg.*, 60:1193–1199.
- 146. Wendling J, Marchand A, Mauviel A , et al. (2003):** Five-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. *Mol Pharmacol.*, 64: 707-713.

- 147. Wu Y, Zhang Q, Ann DK, et al. (2004):** Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. *Am J Physiol Cell Physiol.*, 286: 905-912.
- 148. Wyatt MD and Wilson DM (2009):** Participation of DNA repair in the response to 5-fluorouracil. *Cell Mol Life Sci.*, 6: 788-799.
- 149. Wynn TA (2004):** Fibrotic disease and the T(H)1/T(H)2 paradigm. *Nat Rev Immunol.*, 4: 583–594.

X

- 150. Xia W, Phan T, Lim IJ, et al. (2004):** Complex epithelial-mesenchymal interactions modulate transforming growth factorbeta expression in keloid-derived cells. *Wound Repair Regen.*, 12: 546–556.

Y

- 151. Yamamoto T (2002):** Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma. *Clin Immunol.*, 102:209–216.
- 152. Yamamoto T (2006):** Bleomycin and the skin. *Brit J Dermatol.*, 155: 869–875.
- 153. Yazdanfar A, Farshchian M, Fereydoonnejad M, et al. (2008):** Treatment of Common Warts with an Intralesional Mixture of 5-Fluorouracil, Lidocaine, and Epinephrine: A prospective placebo-controlled, double-blind randomized trial. *Dermatol Surg.*, 34 (5): 656–659.
- 154. Yuste-Garcia P, Villarejo-Campos P, Menendez-Rubio JM, et al. (2006):** Marjolin’s ulcer arising from a laparostomy scar. *Int Surg.*, 91: 207–210.

Z

- 155. Zhang Z, Garron TM, Li XJ, et al. (2009):** Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. *Burns*, 35: 527–537.